View clinical trials related to Covid19.
Filter by:Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19
Background: In the current worldwide medical emergency, a rapid identification of effective therapeutic strategy is crucial. So far, therapy with dexamethasone, remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19, but the effect of baricitinib and remdesivir in combination with dexamethasone. The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency (AIFA-Agenzia Italiana del Farmaco)
Self-swabbing requires less personal protective equipment and could allow to test more people and even to do quick self-diagnosis if antigenic tests are available. In a preliminary study on 190 medical students, the investigators have shown that self and conventional swabbing were identically well-accepted with equivalent level of pain and discomfort induced by swabbing. In a sub-group of this sample, the investigators have shown that the quality of the 2 sampling methods were equivalent. The goal of this large study in the general population is to confirm these findings in an adequately powered study. Such results would allow to develop self-swabbing for large screening campaigns and eventually self-diagnosis using antigenic tests.
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates the efficacy and safety of favipiravir and ribavirin in the treatment of patients with confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in 1:1 ratio and divided into two groups.
2019 coronavirus disease (Covid-19) is a virus that emerged in Wuhan, China in late 2019, spread all over the world in a short time and causes severe acute respiratory syndrome and pneumonia. The World Health Organization classified the COVID-19 outbreak as an "international public health emergency" on January 30 and declared a global epidemic (pandemic) on March 11, 2020, due to the rapid spread of the virus all over the world. speed in the number of cases and deaths. Covidien-19 first cases were reported in Turkey on 10 March 2020 and the number of cases has risen steadily. The total number of COVID-19 cases worldwide on 31.01.2021; It was reported to be 101,917,147 and the total number of deaths was 2,205,515 (https://covid19.who.int/). Considering that the number of cases is constantly increasing, it is obvious that hospitals will not meet the entire epidemic burden. During this period, home care has emerged as an alternative way to effectively alleviate the epidemic burden. Home healthcare during the COVID-19 pandemic; Four roles have stood out: home diagnosis, follow-up, treatment, and care. Protective measures for home isolation of Covid-19 patients are the current method used to prevent the spread of cases. Possible or definite cases that do not have an indication for hospitalization, have a mild clinic and do not accompany severe chronic disease that may lead to a severe course of covid-19 are followed at home until their symptoms improve. In addition, patients who are hospitalized and meet discharge criteria can complete their recovery processes at home. Isolation is terminated on the 14th day at the earliest following the improvement of symptoms in patients who are followed at home. Reducing the contact of people, isolating certain and suspicious cases and effective use of personal protective equipment play an important role in combating the epidemic. It is thought that the training that COVID-19 cases to be followed up and treated at home will be effective in drug compliance, symptom management and quality of life will be effective in the management of the disease. 1251 / 5000 Çeviri sonuçları The universe of the research will be composed of people who apply to Zonguldak Atatürk State Hospital Emergency Service and Covid-19 Polyclinics. . The sample of the study, who accepted to participate in the study, was diagnosed with Covid-19 with U07.3 ICD code according to the results of PCR (Polymerase Chain Reaction) test and Thorax CT (Thorax CT), and was recommended to be followed up and treated at home by the Zonguldak Public Health Department It is planned to create individuals who meet the criteria.
The gut microbiota provides an intestinal biological barrier against pathogens and has a pivotal role in the maintenance of intestinal homeostasis and modulation of the host immune system. The gut microbiota in a dysbiotic state has increasingly been implicated in the pathogenesis and progression of numerous diseases. However, whether dysbiosis reflects changes caused by the disease itself, or should be considered as a driving step in the pathogenesis, is not always understood. Dysbiosis results in the disturbance of several metabolic pathways that influence immunological and mechanical processes both in and outside the intestine, and it impairs colonization resistance. These processes may be reverted by fecal microbiota transplantation (FMT). FMT is a type of treatment that relies on transferring the microbiota that targets and corrects intestinal dysbiosis. FMT is based on collecting stool from healthy donors and - after preparation - administering the material to an individual with a specific disease. In summary, a subset of the symptoms associated with COVID-19 during the initial phase are intestinal complications, such as vomiting or diarrhea. Detecting these symptoms might not only lead to slowdown in transmission but also open the door to novel treatments that could reduce the severity of COVID-19.There is a positive correlation between severity of patient condition and level of proinflammatory cytokines (cytokine storm) in group of patients with COVID 19. Though numerous studies have been published on FMT for the treatment of certain diseases, there are only scarce studies on FMT for the treatment of SARS-CoV-2. Antiviral mechanism depended on the gut-lung axis was intimately proved in case of flu virus. The same dependency is observed in SARS CoV2 as well. That seems, good condition of intestinal microbiota could impact on antiviral effects and inhibits replication of virus. This leads to inhibit progress of inflammatory process in lung tissue. Silencing of inflammatory process through reestablish right influence of gut-lung axis could be fundamental meaning in arresting of cytokines storm and development of ARDS in patients with COVID-19. The scientist rationale definitely argue a clear need to studies of gut wellbeing in COVID 19 and using FMT to reduce development of COVID 19. According to our knowledge FeMToCOVID will be the first clinical trial with using of FMT in COVID 19. We postulate FMT in the beginning of cytokine storm during CIVUD-19 may act as an immunomodulation and stop the progression of the disease.
Recent results demonstrated an increased risk of COVID-19 infection among healthcare workers (HCW), particularly when access to personal protective equipment (PPE) was inadequate. (ref). During the COVID-19 pandemic, access to PPE has become complicated by a surge in worldwide demand combined with production limitations and logistical barriers. Since their introduction in hospitals in the 1990s, filtering facepiece (FFP) masks, mostly of the FFP2 type, are used by HCWs to protect themselves against bioaerosols due to tuberculosis, measles, and selected respiratory viruses. The COVID-19 pandemic has sparked debate around reasonable and safe use of the different types of face masks to protect the HCWs who provide direct care for COVID-19 patients. At the heart of the discussion are the respective contributions to SARS-CoV-2 transmissions by droplets and aerosols, and the corresponding risk levels resulting in COVID-19 infection. The objective is to perform a cluster-randomized, parallel, controlled, non-inferiority study among Swiss nursing and retirement homes to evaluate the efficacy of surgical masks vs. FFP2 masks during patient care and prospectively observe possible infections amongst both vaccinated and unvaccinated staff. Staff in nursing homes will be randomized to use either surgical or FFP2 masks for patient care consistently. Considering an attack rate of 0.8% over three months among healthcare workers, a non-inferiority margin of 5%, and an intracluster variability of 0.01, - we require a minimum of 625 participants per group. The COVID-19 attack rate will be tested by initial serology testing and weekly pooled saliva specimen for SARS-CoV-2 testing. (Re)-Infections will be tracked by weekly pooled saliva-based PCR testing. Exposure to COVID-19 other than during work time will be explored by questionnaires and focus group discussions.
COVID-19 is a new disease , little is known about COVID-19 during pregnancy and to the best of our knowledge no published studies in Assiut . Aims of the Research : 1. To describe COVID-19 among pregnant women attending isolation and women hospitals in Assiut . 2. To identify comorbidities that may affect both maternal , fetal and neonatal outcomes . 3. To correlate between COVID-19 infection and maternal, fetal and neonatal outcomes .
The main objective of this study is to evaluate the efficacy and safety of a single dose of plitidepsin in order to reduce the viral load and symptoms recovery after discharge from Emergency.